Alzheimer's disease biomarkers as predictors of trajectories of depression and apathy in cognitively normal individuals, mild cognitive impairment, and Alzheimer's disease dementia
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objectives: To examine trajectories of depression and apathy over a 5‐year follow‐up period in (prodromal) Alzheimer's disease (AD), and to relate these trajectories to AD biomarkers. Methods: The trajectories of depression and apathy (measured with the Neuropsychiatric Inventory or its questionnaire) were separately modeled using growth mixture models for two cohorts (National Alzheimer's Coordinating Center, NACC, n = 22 760 and Alzheimer's Disease Neuroimaging Initiative, ADNI, n = 1 733). The trajectories in ADNI were associated with baseline CSF AD biomarkers (Aβ 42, t‐tau, and p‐tau) using bias‐corrected multinomial logistic regression. Results: Multiple classes were identified, with the largest classes having no symptoms over time. Lower Aβ 42 and higher tau (ie, more AD pathology) was associated with increased probability of depression and apathy over time, compared to classes without symptoms. Lower Aβ 42 (but not tau) was associated with a steep increase of apathy, whereas higher tau (but not Aβ 42) was associated with a steep decrease of apathy. Discussion: The trajectories of depression and apathy in individuals on the AD spectrum are associated with AD biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Testing the number of components in a normal mixture
Lo, Y. (2001) · Biometrika · doi:10.1093/biomet/88.3.767 · Cited by 4,640
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“The neuropathological changes of AD are extracellular accumulation of amyloid-B peptides in plaques and the intracellular accumulation of hyperphosphorylated tau proteins in neurofibrillary tangles.(6,7) Cerebrospinal fluid (CSF) analytes such as amyloid-β1-42 (Aβ42), phosphorylated-tau (p-tau), and total tau (t-tau)…”
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationThe National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set
Beekly, D. L., Ramos, E. M., Lee, W. W., Deitrich, W. D., Jacka, M. E., Wu, J., Hubbard, J. L., Koepsell, T. D., Morris, J. C., & Kukull, W. A. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318142774e · Cited by 907
Donovan, N. J., Locascio, J. J., Marshall, G. A., Gatchel, J., Hanseeuw, B. J., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Study, F. T. H. A. B. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040442 · Cited by 272
Tschanz, J. T., Corcoran, C. D., Schwartz, S., Treiber, K., Green, R. C., Norton, M. C., Mielke, M. M., Piercy, K., Steinberg, M., Rabins, P. V., et al. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181faec23 · Cited by 244 · cited 1×
“Unlike the deterioration seen for cognition and daily function, “affective” NPS such as depression and apathy do not necessarily progress in one direction over time but rather may persist, remit, or recur episodically.(3) Although depression and apathy frequently cooccur, they also exist separately and it has been arg…”
Self-citationDonovan, N. J., Wadsworth, L. P., Lorius, N., Locascio, J. J., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Marshall, G. A. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.03.006 · Cited by 106 · cited 2×
“Donovan et al reported no association between CSF biomarkers and apathy over time, modeling a single growth trajectory.(11) The primary aim of the present study was to examine whether distinct trajectories of depression and apathy exist in individuals comprising the AD spectrum (ie, cognitively normal [CN], MCI, demen…”
Vermeiren, Y., Le Bastard, N., Van Hemelrijck, A., Drinkenburg, W. H., Engelborghs, S., & De Deyn, P. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.06.010 · Cited by 56 · cited 1×
“3 Although depression and apathy frequently co-occur, they also exist separately and it has been argued that both should be considered as distinct conditions, 4 each with its own biological correlates 5 and course over time.”
Cited by
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13449 · Cited by 113
Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
Costello, H., Roiser, J. P., & Howard, R. (2023) · Psychological Medicine · doi:10.1017/s003329172200397x · Cited by 60
“Recent work using existing large cohorts has identified different trajectories of depressive symptoms in older adults depending on AD biomarker status (Banning, Ramakers, Rosenberg, Lyketsos, & Leoutsakos, 2021).”
Metadata
- Authors
- Banning, L. C. P., Ramakers, I. H. G. B., Rosenberg, P. B., Lyketsos, C. G., Leoutsakos, J. S., & Initiative, A. D. N.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2020-09-11
- Volume
- 36
- Issue
- 1
- Pages
- 224-234
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W3082659809
- Cited by
- 45
- References
- 10
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.